Comprehensive Magnetic Resonance in Peripheral Arterial Disease.3
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented ABI 0.5-0.9
- Ability to walk on treadmill
Exclusion Criteria:
- Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months of enrollment
- Critical limb ischemia
- Known or suspected peripheral neuropathy, heel cord contracture and foot deformity
- Other conditions that limit walking, e.g. lung disease or arthritis
- Active coronary artery disease such as unstable angina, significant left main disease or three vessel coronary artery disease (>70% stenosis, unprotected by grafts) or recent (<2 months) myocardial infarction,
- BMI > 40,
- Known contraindication to MRI (intracardiac pacer, defibrillator, certain intracranial aneurysm clips, intraocular or cochlear implants, claustrophobia, etc.)
- Allergy to lidocaine or xylocaine (local anesthetic)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Home exercise
Patients will undergo home exercise therapy under the supervision of the exercise laboratory
|
Home exercise therapy
|
|
No Intervention: No exercise
Patients will continue with usual care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exercise calf muscle perfusion
Time Frame: Change from baseline at 12 weeks
|
Arterial spin labeling MRI at peak exercise
|
Change from baseline at 12 weeks
|
|
Exercise calf muscle energetics
Time Frame: Change from baseline at 12 weeks
|
Phosphocreatine recovery kinetics by MR spectroscopy at end exercise
|
Change from baseline at 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Calf muscle capillary density
Time Frame: Change from baseline at 12 weeks
|
Biopsy sample of calf muscle for capillary density
|
Change from baseline at 12 weeks
|
|
Treadmill testing
Time Frame: Change from baseline at 12 weeks
|
Treadmill testing with peak VO2 measures
|
Change from baseline at 12 weeks
|
|
6-minute walk test
Time Frame: Change from baseline at 12 weeks
|
6-minute walk test
|
Change from baseline at 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christopher M Kramer, MD, University of Virginia Health System
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-HSR# 16084
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.